Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

Evidence: TAMs are a discrete, monocyte-derived, RBPJ-dependent population

Using the MMTV-PyMT (PyMT) mammary tumor model, myeloid cells comprised >50% of CD45+ tumor-infiltrating leukocytes. Transcriptional classification (PCA against ImmGen datasets plus an SVM) identified "population I" as TAMs: macrophage markers Mafb, CD64, MerTK+ but lacking DC markers (Zbtb46, Flt3, c-Kit); Flt3L-deficient PyMT mice confirmed TAMs are pre-DC-independent (Transcriptional TAM identification in PyMT model1). Critically, the authors separated TAMs (CD11b lo, Vcam1+) from resident mammary tissue macrophages (MTMs, CD11b hi, Mrc1/CD206+), showing TAM frequency rose with tumor burden while MTM frequency fell.

Three independent lineage approaches converged on a monocytic origin: (1) parabiosis showed TAMs and MTMs required circulating input; (2) Ccr2−/− PyMT mice reduced MTMs but not TAMs at 16 and 20 weeks, whereas more potent CCR2-DTR depletion (96% monocyte ablation) reduced both, implying TAMs need less monocyte input because they proliferate locally (higher Ki67 and EdU incorporation than MTMs); (3) adoptive transfer of CCR2+ bone marrow monocytes into depleted hosts showed acquisition of F4/80/CD11c/MHCII, loss of Ly6C/CD11b, and Ki67+ proliferation by day 11 (Lineage-tracing evidence for monocyte origin of TAMs1).

Mechanism and function: Notch/RBPJ and CD8+ T cell tolerance

TAMs unexpectedly lacked canonical "alternatively activated" markers (Ym1, Fizz1, Mrc1); MTMs, not TAMs, resembled AAMs, and Il4−/− PyMT mice had normal TAMs, challenging the blanket M2/TAM equivalence common in earlier literature (Later TAM review retaining M2 framing2). CD11c-cre Rbpjfl/fl PyMT mice selectively lost Vcam1+ TAMs while MTM differentiation was preserved; these mice showed reduced tumor burden (n=13–14), reduced PD-1+ and increased Granzyme B+ CD8+ T cells, effects absent in Flt3l−/− mice lacking DCs, arguing for a TAM-specific, RBPJ-dependent tolerogenic function (RBPJ-dependent TAM differentiation and T cell effects1).

Figure note: the ~50% PD-1+ value at 20 weeks is reported in the text; the 8- and 16-week values are read approximately from the described trend (TAM expansion paralleling exhaustion) and are illustrative, not exact reported numbers. The dashed line indicates the direction of change in CD11c-cre Rbpjfl/fl mice without exact values being reported.

Critical assessment

Strengths: multi-pronged ontogeny logic (parabiosis, genetic depletion, adoptive transfer), transcriptional rather than marker-only identity, a clean DC-depletion control (Flt3l−/−), and public data deposit (GEO GSE56755). Limitations the authors partly acknowledged: single murine model (MMTV-PyMT); RBPJ deletion via CD11c-cre is not TAM-specific (DCs also delete it, mitigated but not eliminated by the Flt3L control); residual TAM intermediates in knockouts may retain pro-tumor activity; human translation left open (Authors1). Blind spots not addressed: no spatial or single-cell resolution (2014 technology), no direct causal demonstration of how TAMs suppress CD8+ T cells (mechanism is correlative), small n in several key panels (n=3 transfers; n=6 depletion), and a provisional MSKCC patent (61/935,318) on TAM-targeted therapy creates a disclosed financial incentive that warrants independent replication (Disclosed patent conflict of interest1). Subsequent work confirmed TAM heterogeneity and origin diversity far exceeding a single monocyte-derived compartment, with stromal crosstalk and spatial positioning shaping TAM states (2024 TAM heterogeneity review3) — consistent with, not falsifying, the paper's model but showing it is one piece of a larger picture. What would falsify the core claim: showing TAMs derive primarily from local self-renewal of resident macrophages in PyMT tumors, or that RBPJ loss reduces tumor burden independent of TAMs.

 BGPT Paper Review

Study Novelty

In 2014, resolving TAM ontogeny from tissue-resident macrophages and implicating Notch/RBPJ was a significant conceptual advance, though macrophage ontogeny frameworks (yolk-sac vs monocyte) were already established by preceding work the paper builds on.

Scientific Quality

Multiple orthogonal lineage approaches, transcriptional classification, and proper DC controls are strong; caveats include small n in transfer experiments, CD11c-cre acting in DCs too, correlative T cell mechanism, and a disclosed patent conflict.

Study Generality

Mechanistic insight into monocyte-to-TAM differentiation and RBPJ dependence generalizes conceptually, but findings are demonstrated in one murine mammary model; authors explicitly note human and other-tumor applicability was untested.

Study Usefulness

Established that TAM depletion spares MTMs and restores CD8+ cytotoxicity, directly informing later TAM-targeted immunotherapy strategies (CSF1R/CCR2/Notch-axis targeting) cited by subsequent reviews.

Study Reproducibility

Flow cytometry gating, mouse strains, and GEO data (GSE56755) support replication, but key figures rely on pooled microarray replicates and some n=3–6 panels; no code release, typical for 2014.

Explanatory Depth

Provides a mechanistic, staged differentiation model (monocyte → proliferating intermediate → Vcam1+ TAM, RBPJ-dependent), though the downstream mechanism linking TAMs to CD8+ T cell exhaustion remains undescribed.